Insmed reports second quarter 2022 financial results and provides business update

--arikayce® (amikacin liposome inhalation suspension) achieves 44% year over year growth for the second quarter of 2022 with total revenue of $65.2 million, marking the strongest quarter since launch -- --all clinical programs progressing on track-- --company reiterates guidance of at least 30% revenue growth in 2022 and cash runway into 2024 to support ongoing programs-- bridgewater, n.j. , aug. 4, 2022 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended june 30, 2022 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking